Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430754 · ClinicalTrials.gov registry record · Phase 3
Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT01430754 is a Phase 3 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT01430754, a Phase 3 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the maintenance effect and safety of 20 mg tasimelteon versus placebo in subjects suffering from Non-24-Hour Sleep-Wake Disorder.
Interventions
- DRUG Placebo
- DRUG tasimelteon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01430754
The ClinicalTrials.gov registry entry for NCT01430754 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01430754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01430754 about?
NCT01430754 is a clinical study titled "Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder". The purpose of this study is to evaluate the maintenance effect and safety of 20 mg tasimelteon versus placebo in subjects suffering from Non-24-Hour Sleep-Wake Disorder.
What is the current status of trial NCT01430754?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2011-09. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01430754?
The interventions under investigation include: Placebo (DRUG), tasimelteon (DRUG).
Who is sponsoring clinical trial NCT01430754?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.